--- title: "MAIA Biotech | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285947817.md" datetime: "2026-05-11T13:02:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285947817.md) - [en](https://longbridge.com/en/news/285947817.md) - [zh-HK](https://longbridge.com/zh-HK/news/285947817.md) --- # MAIA Biotech | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.14. EBIT: As of FY2026 Q1, the actual value is USD -7.062 M. MAIA Biotechnology, Inc. operates as a single segment focused on discovering and developing products for cancer immunotherapies. #### Operational Metrics - **Research and development expenses**: Increased by approximately $327,000, or 10%, from approximately $3,198,000 for the three months ended March 31, 2025, to approximately $3,525,000 for the three months ended March 31, 2026. - **General and administrative expenses**: Increased by approximately $1,197,000, or 54%, from approximately $2,228,000 for the three months ended March 31, 2025, to approximately $3,425,000 for the three months ended March 31, 2026. - **Total operating costs and expenses**: Increased by approximately $1,524,498, or 28%, from approximately $5,425,431 for the three months ended March 31, 2025, to approximately $6,949,929 for the three months ended March 31, 2026. - **Loss from operations**: Increased by approximately - $1,524,498, or 28%, from - $5,425,431 for the three months ended March 31, 2025, to - $6,949,929 for the three months ended March 31, 2026. - **Interest income**: Increased by approximately $29,574, or 36%, from $82,183 for the three months ended March 31, 2025, to $111,757 for the three months ended March 31, 2026. - **Grant income**: Increased by $213,565, from $0 for the three months ended March 31, 2025, to $213,565 for the three months ended March 31, 2026. - **Change in fair value of warrant liability**: Decreased by approximately - $571,034, or -69%, from $825,989 for the three months ended March 31, 2025, to $254,955 for the three months ended March 31, 2026. - **Other income (expense) net**: Decreased by approximately - $327,895, or -36%, from $908,172 for the three months ended March 31, 2025, to $580,277 for the three months ended March 31, 2026. - **Net loss**: Increased by approximately - $1,852,393, or 41%, from - $4,517,259 for the three months ended March 31, 2025, to - $6,369,652 for the three months ended March 31, 2026. #### Cash Flow - **Net cash used in operating activities**: Increased from approximately - $4,202,274 for the three months ended March 31, 2025, to approximately - $5,311,328 for the three months ended March 31, 2026. - **Net cash provided by financing activities**: Increased from approximately $5,461,216 for the three months ended March 31, 2025, to approximately $31,052,321 for the three months ended March 31, 2026. - **Effect of foreign currency exchange on cash**: Increased cash by approximately $14,086 for the three months ended March 31, 2026, compared to an increase of approximately $3,056 for the three months ended March 31, 2025. - **Net increase in cash**: Increased from approximately $1,261,998 for the three months ended March 31, 2025, to approximately $25,755,079 for the three months ended March 31, 2026. #### Liquidity and Capital Resources As of March 31, 2026, MAIA Biotechnology, Inc. had working capital of $28,992,690, an accumulated deficit of - $116,000,657, cash of $34,413,110, and current liabilities of $6,322,437. The company has experienced net losses and negative cash flows from operations since inception and anticipates continued reliance on equity and/or debt financing. #### Financing Activities - **Confidentially Marketed Public Offering (March 2026)**: Issued and sold 20,000,000 shares of common stock for gross proceeds of approximately $30,000,000, with net proceeds of approximately $28,171,000 after commissions and issuance costs. An additional 2,005,875 shares were sold through an over-allotment option for approximately $3,009,000 in gross proceeds, bringing total gross proceeds to approximately $33,000,000. - **Private Placement (February/March 2025)**: Issued and sold 1,810,000 shares and warrants in February 2025 for gross proceeds of approximately $2.7 million, and 952,633 shares and warrants in March 2025 for gross proceeds of approximately $1.4 million. - **At-The-Market (ATM) Offering (2025)**: Sold 666,323 shares of common stock for aggregate gross proceeds of approximately $1,521,091, resulting in net proceeds of approximately $1,390,871. No shares were sold under the ATM agreement in Q1 2026. #### Future Outlook and Strategy MAIA Biotechnology, Inc. plans to seek accelerated approval for ateganosine in the United States for advanced NSCLC in 2026 and initiated a Phase 3 pivotal trial (THIO-104) in 2025, which could lead to early full commercial approval in 2027 and final analysis for full commercial approval in 2028. The net proceeds from the $33 million confidentially marketed public offering in March 2026 are expected to fully fund the ongoing pivotal Phase 3 clinical trial of ateganosine for NSCLC. The company also intends to engage in regulatory interactions with the FDA under its Fast Track designation and plans to start Phase 1 trials for second-generation molecules in 2026. ### Related Stocks - [MAIA.US](https://longbridge.com/en/quote/MAIA.US.md) ## Related News & Research - [MAIA Biotechnology to Terminate ATM Agreement With H.C. Wainwright After Raising $5.68M](https://longbridge.com/en/news/286468852.md) - [MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates | MAIA Stock News](https://longbridge.com/en/news/269416460.md) - [21:15 ETAutonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work](https://longbridge.com/en/news/286985056.md) - [13:01 ETGrowth Catalyst Group Appoints Maia Benson as Chief Commercial Officer](https://longbridge.com/en/news/286596195.md) - [Director Makes Bold Move with Major Stock Purchase in MAIA Biotechnology!](https://longbridge.com/en/news/269168736.md)